Latest News and Press Releases

Revenue of $275.5 Million in Q3 fiscal 2023 increased 0.4% versus Prior Year and 1.8% excluding CurrencyDiluted EPS of $1.04 for Q3 fiscal 2023 increased 5.1% versus Prior YearReduced leverage ratio...

Record Revenue of $289.3 Million in Q2 fiscal 2023 increased 4.7% versus Prior Year and 5.5% excluding CurrencyDiluted EPS of $1.02 for Q2, ahead of expectationsReduced Debt by $35 million in Q2 and...

Company Exceeds Full-Year Earnings Outlook for Revenue, EPS, and Cash FlowRevenue of $266.9 Million in Q4 and $1,086.8 Million for Full-Year Fiscal 2022, up 12.3% and 15.2% versus Prior Year,...

Acquisition adds TheraTears brand to Company’s leading eye care portfolioAcquisition expected to add approximately $60 and $20 million of Revenue and EBITDA, respectively on an annual basisTransaction...

TARRYTOWN, N.Y., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE: PBH) (the “Company”) announced today that its wholly-owned subsidiary, Prestige Brands, Inc. (“Prestige...

TARRYTOWN, N.Y., Jan. 08, 2021 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today announced that it will issue its fiscal 2021 third quarter earnings release on Thursday,...

Revenue was $237.4 Million in Second Quarter Fiscal 2021, Approximately Flat to Prior YearDiluted EPS of $0.88 in Second Quarter Fiscal 2021; Non-GAAP Adjusted Diluted EPS of $0.78 up 15% from Prior...

Revenue was $229.4 Million in First Quarter Fiscal 2021, Down 0.6% from Prior Year Q1 Excluding Unfavorable Foreign CurrencyDiluted EPS of $0.86 in First Quarter Fiscal 2021, up 32% from Prior Year...

TARRYTOWN, N.Y., July 13, 2020 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today announced that it will issue its fiscal 2021 first quarter earnings release on Thursday, August...

Revenue was $251.2 Million in Q4 and $963.0 Million in Full-Year Fiscal 2020Organic Revenue Grew 4.6% in Q4 and 1.3% in Fiscal 2020Generated Cash from Operations of $217.1 Million and Adjusted Free...